Medical education · Dr. Andrea Fischer

04 Jan 2026 · Phone · Dr. Andrea Fischer, Osaka University Hospital · MSL Luis Ortega · Lumeva

ReviewedVeeva CRMENG-0173—

Capture insight from this engagement

Location: Osaka University Hospital
Therapeutic area: Neurology
Country: Japan
Stakeholder tier: Tier 2
Strategic objective: Not linked
Initiative: Not linked
MSL: LOLuis OrtegaMSL, Neurology (Iberia)
Product: Lumeva (lumevarin)

Topics discussed

Dosing in hepatic impairment
Drug interactions
Switching between CGRP agents

Scientific content used

CGRP class review

Questions raised

What is the persistence rate at 18 months in real-world cohorts?
Is there guidance on switching from a monoclonal antibody?

Notes

Medical education with general neurologist at Osaka University Hospital. Discussed dosing in hepatic impairment, drug interactions, switching between cgrp agents.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 5
Strategic relevance: 5
Depth of exchange: 3
Actionability: 3

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0173

Audit history (0)

All create, update and approval events for this record

No audit events in sample data